Posted On: 01/15/2016 12:03:31 AM
Post# of 72447
Rosen is completely out of their league when it comes to understanding even some of the basic concepts of the science behind Cellceutix's drugs. Imho
Just look at how clueless they are about Brilacidin. Maybe Rosen can dazzle common folks with their twisted intentionally misleading BS but Sullivan is going to have the oppotunity to prove to the judge just how clueless the Rosen Law Firm is.
From the ammended complaint :
"Brilacidin will not be eligible to receive a “qualified infectious disease product” designation that would allow a fast-track approval process as an antibiotic.2"
http://ia601507.us.archive.org/4/items/gov.us...4.32.0.pdf
BEVERLY, MA–(Marketwired – November 25, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company’s novel defensin-mimetic Brilacidin, for the prevention of oral mucositis. - See more at: http://cellceutix.com/fda-grants-fast-track-d...OsLii.dpuf
.... is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix’s planned Phase 3 trial of Brilacidin for ABSSSI. - See more at: http://cellceutix.com/cellceutix-antibiotic-b...in-receive
Just look at how clueless they are about Brilacidin. Maybe Rosen can dazzle common folks with their twisted intentionally misleading BS but Sullivan is going to have the oppotunity to prove to the judge just how clueless the Rosen Law Firm is.
From the ammended complaint :
"Brilacidin will not be eligible to receive a “qualified infectious disease product” designation that would allow a fast-track approval process as an antibiotic.2"
http://ia601507.us.archive.org/4/items/gov.us...4.32.0.pdf
BEVERLY, MA–(Marketwired – November 25, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company’s novel defensin-mimetic Brilacidin, for the prevention of oral mucositis. - See more at: http://cellceutix.com/fda-grants-fast-track-d...OsLii.dpuf
.... is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix’s planned Phase 3 trial of Brilacidin for ABSSSI. - See more at: http://cellceutix.com/cellceutix-antibiotic-b...in-receive
(0)
(0)
